(±)-Verapamil . hydrochloride (USP Grade)
35 CHF CHF 35.00
AG-CR1-3627-M100100 mgCHF 35.00
AG-CR1-3627-G0011 gCHF 45.00
AG-CR1-3627-G0055 gCHF 135.00
|Synonyms||NSC135784; NSC272366; NSC657799|
C27H38N2O4 . HCl
|MW||454.6 . 36.5|
|Purity Chemicals||≥99% (NMR)|
|Solubility||Soluble in methanol (50 mg/ml), ethanol or water.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Keep cool and dry.
Protect from light and moisture.
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
- α1-Adrenergic receptor (α-AR) antagonist.
- Prototypical calcium channel protein inhibitor that blocks the L-type Ca2+ channels in smooth and cardiac muscle cells.
- Vasodilator known to reduce the renal clearance of digoxin and used to control hypertension, angina, cardiac arrhythmia and vascular headaches.
- Apoptosis inducer in primary and metastatic colon adenocarcinoma human cell lines in vitro.
- Inhibitor of drug efflux pump proteins such as Mdr (P-glycoprotein) which are often over-expressed in certain tumor cell lines.
- Substrate of CYP3A4 and CYP2C6.
- Used in fluorescent cell sorting for DNA content, as it blocks efflux of a variety of DNA-binding fluorophores such as Hoechst 33342.
- Anti-diabetic in animal models by limiting TXNIP expression.
- New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil: D.P. Zipes & P.J. Troup; Am. J. Cardiol. 41, 1005 (1978) (Review)
- alpha-adrenergic antagonists as possible calcium channel inhibitors: D. Atlas & M. Adler; PNAS 78, 1237 (1981)
- Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics: S.H. Baky & B.N. Singh; Pharmacotherapy 2, 328 (1982) (Review)
- Verapamil: full spectrum calcium channel blocking agent: an overview: J.R. Guerrero & S.S. Martin; Med. Res. Rev. 4, 87 (1984) (Review)
- The calcium channel blocker verapamil and cancer chemotherapy: W.G. Simpson; Cell Calcium 6, 449 (1985) (Review)
- The mechanism of action of calcium antagonists relative to their clinical applications: B.N. Singh; Br. J. Clin. Pharmacol. 21, 109S (1986)
- Enhancement of the mutagenicity of anticancer drugs by the calcium antagonists verapamil and fendiline: W. Scheid, et al.; Arzneimittelforschung 41, 901 (1991) (Review)
- Apoptosis of human primary and metastatic colon adenocarcinoma cell lines in vitro induced by 5-fluorouracil, verapamil, and hyperthermia: I.B. Shchepotin, et al.; Anticancer Res. 14, 1027 (1994)
- Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C: S.K. Rabindran, et al.; Cancer Res. 58, 5850 (1998)
- Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations: T. Kantola, et al.; Clin. Pharmacol. Ther. 64, 177 (1998)
- P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil: M. Verschraagen, et al.; Pharmacol. Res. 40, 301 (1999)
- Preventing β-cell loss and diabetes with calcium channel blockers: G. Xu, et al.; Diabetes 61, 848 (2012)